Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

TimesSquare Capital Management U.S. Small Cap Growth Strategy 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (TimesSquare Capital Management U.S. Small Cap Growth Strategy)

Primary Source Intelligence • Q3 2024 Letter Analysis

TimesSquare Capital Management U.S. Small Cap Growth Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, TimesSquare Capital Management U.S. Small Cap Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+6.24%

Annualized+8.44%

Digest Analysis

Quick Take

"Underperforming benchmarks despite strong individual winners like Boot Barn and Loar Holdings. The team actively rotated positions, adding biotech and hospitality names while exiting underperformers."

Executive Summary

TimesSquare Capital Management's U.S. Small Cap Growth Strategy delivered a 6.24% net return in Q3 2024, underperforming the Russell 2000 Growth Index's 8.41% return. The portfolio benefited from strong performers including Boot Barn (+30%), Loar Holdings (+40%), and OneStream (+37%), while facing headwinds from exits in Savers Value Village (-22%) and European Wax Center (-49%). The team actively managed positions, trimming winners like Clearwater Analytics (+35%) and adding new holdings in biotechnology (Vaxcyte, Insmed) and hospitality (Wyndham Hotels). Key investment themes include AI-driven technology spending, energy sector opportunities tied to commodity prices, and healthcare innovation in vaccines and specialized services. The Federal Reserve's rate cuts provided greater certainty for corporate capital costs, particularly benefiting IT budget planning for 2025. Looking ahead, the team focuses on the pace of central bank easing and November's presidential election impact, maintaining their disciplined approach of finding growth potential relative to valuations while managing downside risks across their diversified small cap portfolio.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The manager demonstrates moderate-high conviction through active position management with specific company names, performance data, and clear rationales for additions and exits. Portfolio holds 90-120 stocks with detailed fundamental analysis, but the diversified approach and hedged language around macro factors caps conviction below high levels.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism about markets with Fed rate cuts providing certainty and stable economic measures, but acknowledges uncertainty around election outcomes and geopolitical tensions. The tone is constructive but measured.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

Portfolio positioning shows selective risk-taking with active trimming of winners and exits from underperformers, while adding new positions in specific sectors. The approach is balanced between opportunity capture and risk management.

Capital Deployment

5%

De-riskingDeploying

De-risking (5%)

Capital deployment appears largely neutral with rotation activity - adding new positions (Wyndham, Vaxcyte, Insmed, OneStream) while exiting others (Savers, European Wax Center, Topgolf). Trimming winners suggests some harvesting. No clear indication of net cash level changes or aggressive deployment.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

Forward guidance is cautious with focus on monitoring central bank policies and election outcomes. The manager emphasizes continued disciplined approach to finding growth relative to valuations while managing risks.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with mentions of opportunities in AI and rate cuts offset by concerns about biopharma spending, geopolitical tensions, and macroeconomic uncertainty. Slightly more constructive than bearish overall.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Manager acknowledges moderate risks including biopharma spending deterioration, macroeconomic concerns affecting client sales cycles, geopolitical tensions, and energy price volatility. Risks are mentioned but not central to the letter's narrative.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

Manager sees selective opportunities across multiple sectors including AI-driven technology spending, energy sector plays, biotechnology innovations, and aerospace/defense. The addition of four new positions suggests a reasonably rich opportunity set, though selectivity is emphasized.

Time Horizon

65%

Short-TermLong-Term

Multi-Year (65%)

The strategy demonstrates a medium-term investment horizon with references to 2025 guidance, multi-year growth initiatives at BJ's, and fundamental research-driven approach. The 54% historical turnover and active position management suggest a 1-3 year investment timeframe rather than permanent capital approach.